Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death

Pfizer, Press Release, NCT05011513, Dec 2021
Hospitalization 70% improvement lower risk ← → higher risk Paxlovid  Pfizer et al.  EARLY TREATMENT RCT Is early treatment with paxlovid beneficial for COVID-19? Double-blind RCT 854 patients in multiple countries (Aug 2021 - Jul 2022) Lower hospitalization with paxlovid (not stat. sig., p=0.051) c19early.org Pfizer, Press Release, December 2021 0 0.5 1 1.5 2+ RR
EPIC-SR trial interim results, 428 patients treated with paxlovid (PF-07321332 + ritonavir) and 426 control patients, showing lower hospitalization with treatment. NCT05011513 (history).
Important missing comments or errors? Let us know.
risk of hospitalization, 70.1% lower, RR 0.30, p = 0.05, treatment 3 of 428 (0.7%), control 10 of 426 (2.3%), NNT 61.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pfizer et al., 14 Dec 2021, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, study period 25 August, 2021 - 25 July, 2022, trial NCT05011513 (history).
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0